

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alan Crossman et al. Int'l Appln. No.: PCT/GB03/003951
U.S. Serial No.: To be assigned Int'l Filing Date: September 11, 2003
Filed: Herewith Docket: 184.4USWO
Title: TREATMENT OF BASAL GANGLIA-RELATED MOVEMENT
DISORDERS WITH 2,3-BENZODIAZEPINES

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

'Express Mail' mailing label number: EV 329956524 US

Date of Deposit: March 8, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service 'Express Mail Post Office To Addressee' service under 37 CFR 1.10 and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: *Barbara Senty*
Name: Barbara Senty

INFORMATION DISCLOSURE STATEMENT(37 C.F.R. §1.97(b))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted within 3-months of the filing date of the above-identified application. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of the International Search Report and a copy of each foreign patent document and each non-patent document listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art". Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please direct any response or inquiry to the below-signed attorney at (310) 641-8797.

Respectfully submitted,

GATES & COOPER LLP
Attorneys for Applicant(s)

Howard Hughes Center
6701 Center Drive West, Suite 1050
Los Angeles, California 90045
(310) 641-8797

Date: March 8, 2005

By: 
Name: William J. Wood
Reg. No.: 42,236

WJW/bjs

Date Mailed:

Sheet 1 of 1

Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Docket Number: 184.4USWO		Int'l Appl. No. PCT/GB03/063951
	Applicant: Alan Crossman et al.		U.S. Serial No.: To be Assigned
	Filing Date: Herewith	Group Art Unit: N/A	

107527271

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	4,322,346	03/30/82	Korosi et al.				
	6,200,970	03/13/01	Ling et al.				

FOREIGN PATENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP0900568	03/10/99	Europe				
	WO02088096	11/07/02	PCT				
	WO02094189	11/28/02	PCT				

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Beers M. and Berkow R., "The Merck Manual of Diagnosis and Therpay, 17 th Edition", 1999, Merck Research Laboratories Whitehouse Station, N.J., pp. 1462-1473, XP002267011.
		Beloborodova et al., "Method of Treatment of Hypertension-Hyperkinetic form of Dyskinesia of Biliiferous Ways in Young Persons", 12/27/02, Abstract, XP002266976.
		Brotchie J.M. et al., "The Effects of Tofisopam on the Actions Induced by L-DOPA Administration in the MPTP - Lesioned Non-Human Primate Model of Parkinson's Disease", Society for Neuroscience Abstract Viewer and Itinerary Planner, Vol. 2002, 2002, page Abstract No. 165.18, XP008026196.
		Konitsiotis S. et al., "AMPA Receptor Blockade Improves Levodopa-Induced Dyskinesia in MPTO Monkeys", Neurology, Vol. 54, No. 8, April 25, 2000, pp. 1589-1595, XP008026187.
		Revutsky E. L. et al., "Prophylaxis of Meteopathological Reactions in Patients with Ischemic heart Disease and Neurocirculatory Dystonia", Vrachebnoe Delo 1988 Russia, No. 2, 1988, pp. 7-10, XP008026189.
		Solyom S. et al., "Non-Competitive AMPA Antagonists of 2,3-Benzodiazepin Type", Current Pharmaceutical Design 2002, Netherlands, Vol. 8, No. 10, 2002, pp. 913-939, XP008026188.
		Tarnawa I. et al., "2,3-Benzodiazepine AMPA Antagonists", Restorative Neurology and Neuroscience, 1998, Vol. 13, pp. 41-57, XP008026184.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

G&C 184.4-US-WO